- Cognition Pharmaceuticals LLC announced positive results from a Phase 2 clinical trial of C105 (l amphetamine sulfate) on 151 Multiple Sclerosis patients with documented cognitive dysfunction.In the six-week placebo-controlled study, Cognition Pharmaceuticals reported, the active group obtained significantly higher scores on secondary outcome measures of memory and learning, including the Brief Visuospatial Memory Test - Revised, Total Recall (p = 0.041) and Delayed Recall (p
< 0.01), and the California Verbal Learning Test, Long Delay Free Recall (p = .012). Safety data were unremarkable with a limited side-effect profile. »Read More
Suggestions, Comments and/or Questions are always appreciated.. - Thank you ============================================
- Cognition Pharmaceuticals LLC announced positive results from a Phase 2 clinical trial of C105 (l amphetamine sulfate) on 151 Multiple Sclerosis patients with documented cognitive dysfunction.In the six-week placebo-controlled study, Cognition Pharmaceuticals reported, the active group obtained significantly higher scores on secondary outcome measures of memory and learning, including the Brief Visuospatial Memory Test - Revised, Total Recall (p = 0.041) and Delayed Recall (p < 0.01), and the California Verbal Learning Test, Long Delay Free Recall (p = .012). Safety data were unremarkable with a limited side-effect profile.
»Read More
Suggestions, Comments and/or Questions are always appreciated.. - Thank you
============================================